hVIVO buys Berlin trials unit for token upfront sum

Health Pharma & Biotech Written by: Ian Lyall 07:17 Thu 27 Aug 2026 --> Proactive has a commercial relationship with hVIVO PLC. This article was produced independently under Proactive's Editorial Standards Policy . Disclaimer No investment advice About this content Editorial Standards & Policies Share article About this content × About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business output at the Daily... Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists. Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. Use of technology Proactive has always been a forward looking and enthusiastic technology adopter. Our human content creators are equipped with many decades of valuable expertise and experience. The team also has access to and use technologies to assist and enhance workflows. Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation. hVIVO PLC ( AIM:HVO ) View Price & Profile hVIVO buys Berlin trials unit for token upfront sum Published: 07:17 27 Aug 2026 BST hVIVO PLC (AIM:HVO) , the clinical trials group, has bought a Berlin clinical research unit for an initial payment of just €250,000, with almost all of the price contingent on future revenue. The company said on Thursday it had acquired the entire share capital of CRS Clinical Research Services Berlin, a specialist site running early-stage studies in dermatology and women's Instead of a fixed price, hVIVO will pay 18% of the Berlin unit's annual revenue for each of the next three years, provided minimum revenue thresholds are met. Management expects that to total roughly €6 million in cash over the period. An existing pension liability of about €2 million will be deducted from those payments, leaving expected net proceeds to the sellers of around €4 million. The structure means the deal is effectively self-funding and leaves hVIVO's cash position intact, a notable feature for a company that has spent the past 18 months expanding by acquisition. hVIVO bought CRS Mannheim and CRS Kiel in January 2025, and the Berlin site has operated alongside those units since, sharing recruitment, quality assurance and IT systems. The company said the acquisition would be immediately earnings accretive and would add to both revenue and earnings before interest, tax, depreciation and amortisation (EBITDA) in the current financial year. CRS Berlin generated unaudited EBITDA of €0.3 million on revenue of €10 million in 2025, a margin of about 3%. Net assets stood at €100,000 at the end of December. Its contracted orderbook was approximately €10 million as at 30 June, covering most of this year's forecast revenue and extending into 2027. The site has 32 beds, 18 of them for intensive monitoring, and has completed more than 350 studies. hVIVO said it was a preferred research site for two of the world's largest pharmaceutical companies. Yamin 'Mo' Khan, chief executive, said dermatology and women's health were large and strategically attractive areas of drug development that meaningfully broadened the group's addressable market. He said the terms reflected a disciplined approach to capital allocation. hVIVO built its reputation on human challenge trials, in which volunteers are deliberately infected with a virus to test vaccines and treatments, and has been diversifying away from that concentration. The new therapeutic areas sit alongside existing work in infectious disease, respiratory, cardiometabolic and immunology. Roughly half of CRS Berlin's proposals to sponsors are already submitted jointly with the Mannheim site. Continue reading